Drug Trial Radar · NCT04626635
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
548
Actual
Start
Dec 21, 2020
Primary completion
Nov 13, 2026
Study completion Mar 5, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
Conditions
- Advanced Solid Tumors
Interventions
REGN7075Drug
Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
CemiplimabDrug
Administered concomitantly Q3W by IV infusion or SC injection
Platinum-based doublet chemotherapyDrug
Administered IV Q3W
BevacizumabDrug
Administered per protocol
Trifluridine-tipiracilDrug
Administered per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of Dose-Limiting Toxicities (DLTs) during the DLT periodTime frame: Up to 6 weeks
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 90 days from last dose; up to 5 years
- Incidence and severity of Adverse Events of Special Interest (AESIs)Time frame: Approximately 90 days from last dose; up to 5 years
- Incidence and severity of Serious Adverse Events (SAEs)Time frame: Approximately 90 days from last dose; up to 5 years
- Incidence and severity of grade ≥3 laboratory abnormalitiesTime frame: Approximately 90 days from last dose; up to 5 years
- Objective Response Rate (ORR)Time frame: Up to 5 years
Locations
54 sites in 7 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
University of California Los Angeles (UCLA) Medical Center
Los Angeles, California
The Regents of the University of California, San Francisco
San Francisco, California
University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic
Aurora, Colorado
University of Florida Health
Gainesville, Florida
Moffitt Cancer Center
Tampa, Florida
University of Illinois Cancer Center
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
START Midwest - Cancer & Hematology Centers of Western Michigan, PC
Grand Rapids, Michigan
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
The Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute - 25th Ave
Nashville, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
South Texas Oncology And Hematology
San Antonio, Texas
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Hospital Paris Saint-Joseph
Paris, France
Centre Leon Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL)
Lyon, Auvergne-Rhone, France
Hopital Lyon Sud
Pierre-Bénite, Auvergne-Rhône, France
Centre Georges Francois Leclerc
Dijon, Bourgogne-Franche-Comté, France
Institut Claudius Regaud, IUCT-Oncopole
Toulouse, Haute-Garonne, France
Centre Hospitalier Universitaire (CHU) de Lille
Lille, Hauts-de-France, France
Begin Army Instruction Hospital
Saint-Mandé, Île-de-France Region, France
Gustave Roussy
Villejuif, Île-de-France Region, France
Institut Bergonie
Bordeaux, New Aquitaine, France
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, New Aquitaine, France
Nantes University Hospital
Nantes, Pays de la Loire Region, France
Centre Antoine Lacassagne
Nice, Provence Alpes Cote dAzur, France
Soroka University Medical Center
Beersheba, Israel
Rambam Health Care Campus
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Hadassah Medical Center
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sheba Medical Center
Ramat Gan, Central District, Israel
Netherlands Cancer Institute
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.